KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.90

Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial.

Andrew J Armstrong, Fred Saad, Mototsugu Oya, Neal Shore, Giuseppe Procopio, Cagatay Arslan, Niven Mehra, Emma Brown, Jae Young Joung, Mikio Sugimoto, Mustafa Özgüroğlu, Craig Gedye, Oliver Sartor, Christian Poehlein, Ping Qiu, Yu-Zhen Liu, Xiaodun Li, Elizabeth A Harrington, David McGuinness, Jinyu Kang, Alan Barnicle, Noel Clarke

JCO Precis Oncol 10(5) e2501109

PMID42114035
PMCIDPMC13182812
DOI10.1200/PO-25-01109
发表日期2026-05-11
入排依据:This record reports on biomarker detection methodology and concordance analyses from the PROpel Phase III trial, not the primary efficacy results (e.g., rPFS or OS). It is an ancillary, secondary analysis.
已检查 5 张 PubMed Figure,均未识别为 KM 图:FIG 1.:AI 判定为 flow diagram;FIG 2.:AI 判定为 flow diagram;FIG 3.:ROC 图;FIG 4.:AI 判定为 other;FIG 5.:AI 判定为 other。
摘要

摘要

PURPOSE: In the PROpel study (ClinicalTrials.gov identifier: NCT03732820), olaparib plus abiraterone demonstrated statistically significant radiographic progression-free survival benefit versus placebo plus abiraterone in a first-line metastatic castration-resistant prostate cancer (mCRPC) population unselected by homologous recombination repair gene mutation (HRRm) status. From PROpel, we report exploratory biomarker analyses assessing HRRm and BRCA1 and/or BRCA2 (BRCAm) status using tumor tissue and plasma-derived circulating tumor (ct) DNA. METHODS: Patients received (1:1) either olaparib (300 mg twice a day) or placebo in combination with abiraterone (1,000 mg once daily) plus prednisone/prednisolone (5 mg twice a day). Tumor tissue and ctDNA samples were analyzed using FoundationOne CDx and FoundationOne Liquid CDx tests, respectively. Biomarker results are presented by individual tests and as an aggregate analysis. RESULTS: HRRm status was obtained for 778 of 796 (98%) patients randomly assigned. Aggregating tumor tissue and ctDNA results, 226 patients were identified as having HRRm (including 85 BRCAm). In matched tumor tissue and ctDNA samples (n = 491), and using the tumor tissue result as the reference, high concordance was observed for HRRm (overall percent agreement, 85.1%; negative predictive value, 93.7%) and BRCAm status (overall percent agreement, 93.9%; negative predictive value, 97.3%), with low ctDNA fraction being a limiting factor in rare cases where discordance was observed. Based on the observed agreement, there was a potential incidence of 1% unidentified BRCAm in aggregated non-BRCAm patients (n = 693). CONCLUSION: Aggregating tumor tissue and ctDNA analyses maximized the number of patients (98%) with known biomarker status in PROpel while limiting the number of potential false negatives. This represents the most comprehensive means for identifying biomarker-positive and biomarker-negative subgroups and demonstrates the complementary utility of ctDNA testing in mCRPC, particularly when tissue testing is unable to provide a clinically useful result.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. PROpel study patient disposition.
非 KM Figure
FIG 2.FIG 2. Flowchart of tumor tissue and ctDNA-based testing of patients randomly assigned in the PROpel study. ctDNA, circulating tumor DNA; HRRm, homologous recombination repair mutation.
非 KM Figure
FIG 3.FIG 3. (A) Reasons for not obtaining a tumor tissue or ctDNA-based test result and proportion of tumor test results obtained by (B) the collection method or tumor type and (C) sample age. QC metric fail refers to samples that did not meet the minimum QC metrics and/or additional QC thresholds of Foundation Medicine's standards for laboratory processing in the step of DNA extraction, library construction, or hybrid capture. Collection method: The other/unknown category is specific to needle aspiration cytology (n = 3), trephine biopsy (n = 3), and cases where the collection method is not specified (n = 2). Sample type (primary v metastatic tumor): The other/unknown category is specific to when the organ site of collection is not stated. ctDNA, circulating tumor DNA; HRRm, homologous recombination repair gene mutation; QC, quality control; TURP, transurethral resection of the prostate.
非 KM Figure
FIG 4.FIG 4. Patient-matched tumor and ctDNA sample results in HRR genes with overlaid ctDNA fraction estimates per patient. ctDNA, circulating tumor DNA; HRR, homologous recombination repair; HRRm, homologous recombination repair gene mutation.
非 KM Figure
FIG 5.FIG 5. Evaluable ctDNA fraction rate and predicted tumor fraction (%) in the context of (A) HRRm status and (B) BRCAm status. BRCAm, BRCA1 or BRCA2 mutation; ctDNA, circulating tumor DNA; HRRm, homologous recombination repair gene mutation.
非 KM Figure